Literature DB >> 2881820

Use of a combined DTP-polio vaccine in a reduced schedule.

T A Swartz, M Roumiantzeff, L Peyron, T Stopler, J Drucker, I Epstein, L Leitner, N Goldblum.   

Abstract

A five-year serologic follow-up and a four-year monitoring of the polio and pertussis morbidity in an area immunized with a 2 + 1 dose schedule of a combined DTP-Po vaccine have shown that: the individual protection against polio measured by the presence of neutralizing antibody persists at a very adequate level five years after the first booster; after three years of a steady high proportion of children with pertussis antibody, a considerable drop is observed and in about 28% of individuals agglutinin levels of less than 1:20 were found five years after booster; the community protection against paralytic poliomyelitis and pertussis is satisfactory up to four years after the introduction of the program. Continuation of immunization with a 2 + 1 dose schedule at a maximal coverage and close seroepidemiologic surveillance are necessary in order to draw definite conclusions, because of the potentially strong impact of very dynamic ecological factors present in our geopolitical area upon the agent-host interrelationship.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2881820

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  2 in total

1.  Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies.

Authors:  Sonia Resik; Alina Tejeda; Magile Fonseca; Carolyn Sein; Lai Heng Hung; Yenisleidys Martinez; Manuel Diaz; Hiromasa Okayasu; Roland W Sutter
Journal:  Trials Vaccinol       Date:  2015

2.  Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Authors:  Siddhartha Kumar Bhaumik; Raveendra R Kulkarni; William C Weldon; Eduardo L V Silveira; Hasan Ahmed; Sivaram Gunisetty; Anmol Chandele; Rustom Antia; Harish Verma; Roland Sutter; Mark A Pallansch; M Steven Oberste; Francois Villinger; Walter Orenstein; Kaja Murali-Krishna
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.